Synthesis and evaluation of adenosine derivatives as A1, A2A, A2B and A3 adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A3 agonists

Eur J Med Chem. 2021 Nov 5:223:113607. doi: 10.1016/j.ejmech.2021.113607. Epub 2021 Jun 11.

Abstract

A series of adenosine and 2'-deoxyadenosine pairs modified with a 1,12-dicarba-closo-dodecaborane cluster or alternatively with a phenyl group at the same position was synthesized, and their affinity was determined at A1, A2A, A2B and A3 adenosine receptors (ARs). While AR affinity differences were noted, a general tendency to preferentially bind A3 AR over other ARs was observed for most tested ligands. In particular, 5'-ethylcarbamoyl-N6-(3-phenylpropyl)adenosine (18), N6-(3-phenylpropyl)-2-chloroadenosine (24) and N6-(3-phenylpropyl)adenosine (40) showed nanomolar A3 affinity (Ki 4.5, 6.4 and 7.5 nM, respectively). Among the boron cluster-containing compounds, the highest A3 affinity (Ki 206 nM) was for adenosine derivative 41 modified at C2. In the matched molecular pairs, analogs bearing boron clusters were found to show lower binding affinity for adenosine receptors than the corresponding phenyl analogs. Nevertheless, interestingly, several boron cluster modified adenosine ligands showed significantly higher A3 receptor selectivity than the corresponding phenyl analogs: 7vs. 8, 15vs. 16, 17vs. 18.

Keywords: Adenosine; Agonists; Antagonists; Boron cluster; Nucleosides; Purinergic receptors; Selectivity.

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / metabolism
  • Adenosine / pharmacology*
  • Adenosine A3 Receptor Agonists / chemical synthesis
  • Adenosine A3 Receptor Agonists / metabolism
  • Adenosine A3 Receptor Agonists / pharmacology*
  • Animals
  • Boron Compounds / chemical synthesis
  • Boron Compounds / metabolism
  • Boron Compounds / pharmacology
  • CHO Cells
  • Cricetulus
  • HEK293 Cells
  • Humans
  • Ligands
  • Molecular Structure
  • Platelet Aggregation Inhibitors / chemical synthesis
  • Platelet Aggregation Inhibitors / metabolism
  • Platelet Aggregation Inhibitors / pharmacology
  • Receptor, Adenosine A3 / metabolism*
  • Structure-Activity Relationship

Substances

  • Adenosine A3 Receptor Agonists
  • Boron Compounds
  • Ligands
  • Platelet Aggregation Inhibitors
  • Receptor, Adenosine A3
  • Adenosine